✦ LIBER ✦

A pharmacokinetic model to differentiate preabsorptive, gut epithelial, and hepatic first-pass metabolism

✍ Scribed by Wayne A. Colburn

Book ID: 112473648
Publisher: Springer
Year: 1979
Tongue: English
Weight: 469 KB
Volume: 7
Category: Article
ISSN: 1573-8744
DOI: 10.1007/bf01062538

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Differentiation of absorption and first-

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*

✍ Wu, Chi-Yuan; Benet, Leslie Z.; Hebert, Mary F.; Gupta, Suneel K.; Rowland, Malc 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 604 KB

The low and variable bioavailability of cyclosporine has been attributed to poor absorption. However, recent studies have suggested that intestinal first-pass metabolism exerts a significant effect on bioavailability. We describe theory and methods to differentiate the contribution from oral absorpt

A semiphysiological pharmacokinetic mode

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction

✍ Toufigh Gordi; Rujia Xie; Nguyen V. Huong; Dinh X. Huong; Mats O. Karlsson; Mich 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 617 KB

Pharmacokinetics of DA-8159, a new erect

Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects

✍ Hyun J. Shim; Yu C. Kim; Kyung J. Park; Dong S. Kim; Jong W. Kwon; Won B. Kim; M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

The purposes of this study were to report dose-independent (after intravenous administration) and dose-dependent (after oral administration) area under the curve of plasma concentration versus time from time zero to time infinity (AUC), and gastric, intestinal, and/or hepatic first-pass effects (aft

Dose-dependent pharmacokinetics of a new

Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect

✍ Eun J. Kim; Sun-O. Kim; Dong H. Lee; Hong Lim; Myung G. Lee 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 2 views

Pharmacokinetics of a new reversible pro

Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats

✍ Kye S. Han; Yoon G. Kim; Joong K. Yoo; Jong W. Lee; Myung G. Lee 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 1 views

The pharmacokinetics of YH1885 were evaluated after intravenous (iv) and oral administrations of the drug to rats and dogs. The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (G

Dose-independent pharmacokinetics of a n

Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects

✍ Mi H. Lee; Soo K. Bae; Eun J. Kim; Yoon G. Kim; Sun-O. Kim; Dong H. Lee; Hong Li 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

The purpose of this study was to report dose-independent pharmacokinetics of KR-31543, a new neuroprotective agent for ischemia-reperfusion damage, after intravenous (iv) and oral (po) administration and first-pass effects after iv, intraportal, intragastric, and intraduodenal administration in rats